Grace Therapeutics, Inc.
Income Statement
| Line Item | FY2022 | FY2021 |
|---|---|---|
| Revenue | $100.0M | $196.0K |
| Cost of Revenue | $0 | $76.0K |
| Gross Profit | $100.0M | $120.0K |
| Gross Margin | 100.0% | 61.2% |
| Operating Expenses | ||
| Research & Development | $5.6M | $4.2M |
| SG&A Expense | $9.3M | $5.5M |
| Operating Income | $-15.6M | $-16.4M |
| Operating Margin | -15.6% | -8,377.0% |
| Interest Expense | — | — |
| Pretax Income | $-10.5M | $-19.7M |
| Income Tax Expense | $-648.0K | $0 |
| Net Income | $-9.8M | $-19.7M |
| Net Margin | -9.8% | -10,039.8% |
| EPS (Basic) | $-0.27 | $-1.33 |
| EPS (Diluted) | $-0.27 | $-1.33 |
| Shares Outstanding (Basic) | 36.8M | 208.4M |
| Shares Outstanding (Diluted) | 36.8M | 208.4M |
| Dividends Per Share | — | — |